IFNB1 and relapsing-remitting multiple sclerosis: To study the effect of in vivo IFN–β therapy on monocytic HGF secretion in RRMS patients, we compared cell-associated HGF levels in CD14+ monocytes from RRMS patients treated with IFN-β to those of age– and sex–matched untreated patients (see Table 1).